Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
However, it is important to disclose all medications you are taking to your healthcare provider, as empagliflozin can interact with other drugs
Gradual dose increases improve tolerance and long-term treatment success
Appetite and dietary intake can be assessed through patient-reported outcomes, food diaries, or validated questionnaires
When Asian-adjusted cutoffs were applied, the eligible population increased substantially in Asian regions
Still, they will work best as one part of a whole-person, whole-picture approach alongside lifestyle change and other integrative support
